← Leaderboards
Elizabeth Jane Franzmann
University Of Miami School Of Medicine
$3,381,587
Attributed
$5,793,423
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,793,423 · 6
By mechanism
R01$3,978,997 · 2
R44$1,021,347 · 1
R21$422,125 · 1
R43$219,454 · 1
R03$151,500 · 1
Top collaborators
- Joseph A Califano6 shared
- Isildinha Marques Reis2 shared
- Paolo Serafini2 shared
- Donald Topping Weed2 shared
- Xi Steven Chen1 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Paolo Serafini$2,304,023
- Donald Topping Weed$140,708
- Midhat H Abdulreda$2,833,074
Others in their field
Top investigators on “Early Diagnosis”
- Michael W Weiner · Northern California Institute Res &Educ$162,576,753
- Mitchell D Schnall · University Of Pennsylvania$148,421,012
- David Heimbrook · Leidos Biomedical Research, Inc.$98,656,722
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$85,695,840
- Sharon A Nachman · Johns Hopkins University$77,262,665
- Peter J O'Dwyer · University Of Pennsylvania$75,791,391
Research focus
Early DiagnosisOralDetectionCd44 GeneMalignant NeoplasmsBaseMalignant Mouth NeoplasmSurvival RateRisk FactorsDiagnosisPerformanceCase-Control StudiesSalivaryResearch DesignTobaccoMorbidity - Disease RateCancer DiagnosisOral CavityAlcoholsProteinsSalivaSpecificityProgramsDiagnostic Tests
Grant awards (18)
Development of an effective, low-cost, point-of-care early detection test for oral cancer in low resource settings$1,021,347
R44 · FY2025 · CA · contact PI
Aptamer specific for myeloid derived suppressor cells for the diagnosis of head and neck cancer from the oral rinse$230,250
R21 · FY2024 · DE
Aptamer specific for myeloid derived suppressor cells for the diagnosis of head and neck cancer from the oral rinse$191,875
R21 · FY2023 · DE
A novel point of care test for oral and oropharyngeal cancer risk$530,862
R01 · FY2021 · CA
A novel point of care test for oral and oropharyngeal cancer risk$512,031
R01 · FY2020 · CA
A novel point of care test for oral and oropharyngeal cancer risk$488,480
R01 · FY2019 · CA
A novel point of care test for oral and oropharyngeal cancer risk$554,293
R01 · FY2018 · CA
A novel point of care test for oral and oropharyngeal cancer risk$593,922
R01 · FY2017 · CA
Optical imaging of a CD44-based oral-rinse with fluorescent detection to visualize oral cancer$27,916
R43 · FY2017 · DE · contact PI
Optical imaging of a CD44-based oral-rinse with fluorescent detection to visualize oral cancer$191,538
R43 · FY2016 · DE · contact PI
Salivary Soluble Markers in Head and Neck Cancer$121,219
R01 · FY2010 · CA · contact PI
Salivary Soluble Markers in Head and Neck Cancer$303,439
R01 · FY2009 · CA · contact PI
Salivary Soluble Markers in Head and Neck Cancer$147,337
R01 · FY2009 · CA · contact PI
Salivary Soluble Markers in Head and Neck Cancer$302,644
R01 · FY2008 · CA · contact PI
Salivary Soluble Markers in Head and Neck Cancer$122,126
R01 · FY2008 · CA · contact PI
Salivary Soluble Markers in Head and Neck Cancer$302,644
R01 · FY2007 · CA · contact PI
Salivary Soluble CD44: A Molecular Marker for Head and *$75,750
R03 · FY2005 · CA
Salivary Soluble CD44: A Molecular Marker for HNSCC$75,750
R03 · FY2004 · CA